CPS 2001 to build poppy-based pharma factory in Hungary

9 November 2001

Hungarian firm Central European Poppy Systems 2001 Rt has started tobuild a new pharmaceutical manufacturing facility at the Szikszo industrial park in the northern part of the country, with an investment of 2 billion forint ($7.1 million), reports New World Publishing.

According to the firm's chief executive, Miklos Szima Marmarosi, CPS 2001 is owned by private investors and has a registered capital of 58 million forint. It plans to make tranquilizers and morphine from poppies at the new factory, which will initially employ 100 people, with this figure set to rise to 300 from 2004, Mr Marmarosi told the news agency.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight